

Johannes G Ramaekers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9361421/publications.pdf>

Version: 2024-02-01

146
papers

6,846
citations

66343

42
h-index

74163

75
g-index

151
all docs

151
docs citations

151
times ranked

4973
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose related risk of motor vehicle crashes after cannabis use. <i>Drug and Alcohol Dependence</i> , 2004, 73, 109-119.	3.2	475
2	High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control. <i>Neuropsychopharmacology</i> , 2006, 31, 2296-2303.	5.4	322
3	Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. <i>Journal of Psychopharmacology</i> , 2009, 23, 266-277.	4.0	294
4	An Experimental Study of Catechol-O-Methyltransferase Val158Met Moderation of Δ^9 -Tetrahydrocannabinol-Induced Effects on Psychosis and Cognition. <i>Neuropsychopharmacology</i> , 2006, 31, 2748-2757.	5.4	288
5	Cognition and motor control as a function of Δ^9 -THC concentration in serum and oral fluid: Limits of impairment. <i>Drug and Alcohol Dependence</i> , 2006, 85, 114-122.	3.2	262
6	Marijuana, alcohol and actual driving performance. <i>Human Psychopharmacology</i> , 2000, 15, 551-558.	1.5	248
7	Antidepressants and Driver Impairment. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 20-29.	2.2	211
8	On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. <i>Sleep</i> , 2019, 42, .	1.1	205
9	Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. <i>Progress in Neurobiology</i> , 2020, 185, 101732.	5.7	159
10	Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. <i>Psychopharmacology</i> , 2018, 235, 2979-2989.	3.1	134
11	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. <i>Psychopharmacology</i> , 2019, 236, 2713-2724.	3.1	130
12	Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. <i>Neuropsychopharmacology</i> , 2020, 45, 2003-2011.	5.4	127
13	Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. <i>Psychopharmacology</i> , 2011, 214, 391-401.	3.1	125
14	Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. <i>Psychopharmacology</i> , 2016, 233, 3395-3403.	3.1	125
15	Smoked Cannabis' Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers. <i>Journal of Analytical Toxicology</i> , 2015, 39, 251-261.	2.8	106
16	Effect of Cannabidiol and Δ^9 -Tetrahydrocannabinol on Driving Performance. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2177.	7.4	106
17	A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. <i>Psychopharmacology</i> , 2019, 236, 2653-2666.	3.1	99
18	Acute Effects of 3,4-Methylenedioxymethamphetamine (MDMA) on Behavioral Measures of Impulsivity: Alone and in Combination with Alcohol. <i>Neuropsychopharmacology</i> , 2006, 31, 1048-1055.	5.4	95

#	ARTICLE	IF	CITATIONS
19	Medicinal δ^9 -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests. <i>Addiction</i> , 2012, 107, 1837-1844.	3.3	91
20	Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 20-9.	2.2	85
21	Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT ₂ and 5-HT ₁ Receptors. <i>PLoS ONE</i> , 2012, 7, e40187.	2.5	77
22	Dissociable Effects of a Single Dose of Ecstasy (MDMA) on Psychomotor Skills and Attentional Performance. <i>Journal of Psychopharmacology</i> , 2003, 17, 379-387.	4.0	76
23	Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 140, 215-222.	2.8	73
24	No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT _{1a} Receptor Activation. <i>PLoS ONE</i> , 2014, 9, e100719.	2.5	72
25	Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 461-466.	4.9	71
26	Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. <i>Journal of Psychopharmacology</i> , 2017, 31, 589-598.	4.0	70
27	Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence. <i>PLoS ONE</i> , 2013, 8, e53127.	2.5	69
28	Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. <i>Addiction</i> , 2006, 101, 1614-1621.	3.3	64
29	Pharmacokinetic Properties of Δ^9 -Tetrahydrocannabinol in Oral Fluid of Occasional and Chronic Users. <i>Journal of Analytical Toxicology</i> , 2010, 34, 216-221.	2.8	62
30	Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. <i>European Neuropsychopharmacology</i> , 2020, 41, 81-91.	0.7	62
31	Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. <i>Psychopharmacology</i> , 2020, 237, 773-785.	3.1	61
32	Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 543-552.	4.9	58
33	The sensitivity of laboratory tests assessing driving related skills to dose-related impairment of alcohol: A literature review. <i>Accident Analysis and Prevention</i> , 2016, 89, 31-48.	5.7	54
34	A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid. <i>Psychopharmacology</i> , 2012, 223, 439-446.	3.1	52
35	Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes. <i>Brain Imaging and Behavior</i> , 2016, 10, 1254-1263.	2.1	52
36	Quantification of endogenous neurotransmitters and related compounds by liquid chromatography coupled to tandem mass spectrometry. <i>Talanta</i> , 2019, 192, 93-102.	5.5	51

#	ARTICLE	IF	CITATIONS
37	A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. <i>Psychopharmacology</i> , 2021, 238, 1899-1910.	3.1	51
38	Cannabis and tolerance: acute drug impairment as a function of cannabis use history. <i>Scientific Reports</i> , 2016, 6, 26843.	3.3	50
39	Sensitivity and Validity of Psychometric Tests for Assessing Driving Impairment: Effects of Sleep Deprivation. <i>PLoS ONE</i> , 2015, 10, e0117045.	2.5	49
40	Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance. <i>European Neuropsychopharmacology</i> , 2020, 36, 191-205.	0.7	48
41	A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2021, 35, 398-405.	4.0	47
42	Methylphenidate reduces functional connectivity of nucleus accumbens in brain reward circuit. <i>Psychopharmacology</i> , 2013, 229, 219-226.	3.1	46
43	Spontaneous and deliberate creative cognition during and after psilocybin exposure. <i>Translational Psychiatry</i> , 2021, 11, 209.	4.8	46
44	Driving Under the Influence of Cannabis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1433.	7.4	45
45	Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity. <i>European Neuropsychopharmacology</i> , 2019, 29, 247-256.	0.7	45
46	Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 138, 104689.	6.1	45
47	A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., "weaving") while driving at a blood alcohol concentration of 0.5 g/L. <i>Psychopharmacology</i> , 2017, 234, 837-844.	3.1	41
48	Blockade of 5-HT ₂ Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment. <i>Neuropsychopharmacology</i> , 2011, 36, 1932-1939.	5.4	40
49	Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 79-86.	2.4	39
50	Involvement of Inferior Parietal Lobules in Prospective Memory Impairment during Acute MDMA (Ecstasy) Intoxication: An Event-Related fMRI Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1641-1648.	5.4	39
51	Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure. <i>Psychopharmacology</i> , 2016, 233, 3331-3340.	3.1	37
52	Drugs and Driving Research in Medicinal Drug Development. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 319-321.	8.7	36
53	The why behind the high: determinants of neurocognition during acute cannabis exposure. <i>Nature Reviews Neuroscience</i> , 2021, 22, 439-454.	10.2	36
54	Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. <i>British Journal of Pharmacology</i> , 2018, 175, 18-28.	5.4	34

#	ARTICLE	IF	CITATIONS
55	The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. <i>Journal of Psychopharmacology</i> , 2022, 36, 309-320.	4.0	34
56	Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. <i>Drug Testing and Analysis</i> , 2016, 8, 682-689.	2.6	33
57	Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. <i>Psychopharmacology</i> , 2011, 215, 321-332.	3.1	32
58	Detection of Δ^9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. <i>Drug Testing and Analysis</i> , 2019, 11, 1486-1497.	2.6	32
59	Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. <i>Addiction Biology</i> , 2021, 26, e12870.	2.6	31
60	Fatigue in Aviation: Safety Risks, Preventive Strategies and Pharmacological Interventions. <i>Frontiers in Physiology</i> , 2021, 12, 712628.	2.8	31
61	The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). <i>Journal of Neurochemistry</i> , 2022, 162, 128-146.	3.9	31
62	Intoxicated aggression: Do alcohol and stimulants cause dose-related aggression? A review. <i>European Neuropsychopharmacology</i> , 2020, 30, 114-147.	0.7	30
63	Memory and mood during MDMA intoxication, with and without memantine pretreatment. <i>Neuropharmacology</i> , 2014, 87, 198-205.	4.1	28
64	MDMA, cannabis, and cocaine produce acute dissociative symptoms. <i>Psychiatry Research</i> , 2015, 228, 907-912.	3.3	28
65	Human orbital and anterior medial prefrontal cortex: Intrinsic connectivity parcellation and functional organization. <i>Brain Structure and Function</i> , 2017, 222, 2941-2960.	2.3	28
66	Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. <i>Psychopharmacology</i> , 2015, 232, 343-353.	3.1	26
67	Evaluation of Δ^9 -tetrahydrocannabinol detection using DrugWipe5S [®] screening and oral fluid quantification after Quantisal [®] collection for roadside drug detection via a controlled study with chronic cannabis users. <i>Drug Testing and Analysis</i> , 2015, 7, 178-186.	2.6	26
68	Influence of Long-Term Benzodiazepine use on Neurocognitive Skills Related to Driving Performance in Patient Populations: A Review. <i>Pharmacopsychiatry</i> , 2017, 50, 189-196.	3.3	26
69	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. <i>Psychopharmacology</i> , 2019, 236, 2677-2685.	3.1	26
70	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 658-666.	4.7	26
71	Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 89-98.	2.4	25
72	Driving Performance of Depressed Patients who are Untreated or Receive Long-Term Antidepressant (SSRI/SNRI) Treatment. <i>Pharmacopsychiatry</i> , 2017, 50, 182-188.	3.3	24

#	ARTICLE	IF	CITATIONS
73	Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being. <i>Frontiers in Pharmacology</i> , 2021, 12, 721537.	3.5	24
74	On-the-road driving performance and driving-related skills in older untreated insomnia patients and chronic users of hypnotics. <i>Psychopharmacology</i> , 2014, 231, 2851-65.	3.1	22
75	Neurocognitive performance following acute mephedrone administration, with and without alcohol. <i>Journal of Psychopharmacology</i> , 2016, 30, 1305-1312.	4.0	22
76	Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication. <i>Addiction Biology</i> , 2017, 22, 823-832.	2.6	22
77	A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 442-453.	2.4	22
78	Metabolomics predicts the pharmacological profile of new psychoactive substances. <i>Journal of Psychopharmacology</i> , 2019, 33, 347-354.	4.0	21
79	Cannabis increases susceptibility to false memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4585-4589.	7.1	21
80	Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory. <i>British Journal of Pharmacology</i> , 2013, 168, 607-617.	5.4	20
81	Acute effects of cocaine and cannabis on reversal learning as a function of COMT and DRD2 genotype. <i>Psychopharmacology</i> , 2016, 233, 199-211.	3.1	20
82	Hazy memories in the courtroom: A review of alcohol and other drug effects on false memory and suggestibility. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 124, 291-307.	6.1	20
83	A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. <i>Frontiers in Pharmacology</i> , 2021, 12, 760671.	3.5	20
84	Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity. <i>Journal of Psychopharmacology</i> , 2015, 29, 324-334.	4.0	19
85	Orbital and Medial Prefrontal Cortex Functional Connectivity of Major Depression Vulnerability and Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 348-357.	1.5	19
86	Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective. <i>PLoS ONE</i> , 2016, 11, e0149438.	2.5	19
87	Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study. <i>Psychopharmacology</i> , 2022, 239, 1839-1852.	3.1	19
88	Acute effects of cocaine and cannabis on response inhibition in humans: an ERP investigation. <i>Addiction Biology</i> , 2016, 21, 1186-1198.	2.6	18
89	Effect of chronic opioid therapy on actual driving performance in non-cancer pain patients. <i>Psychopharmacology</i> , 2017, 234, 989-999.	3.1	18
90	Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 51-61.	2.9	18

#	ARTICLE	IF	CITATIONS
91	Driving performance and neurocognitive skills of long-term users of benzodiazepine anxiolytics and hypnotics. <i>Human Psychopharmacology</i> , 2019, 34, e2715.	1.5	18
92	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. <i>Addiction Biology</i> , 2022, 27, e13125.	2.6	18
93	Influence of Ethanol on the Pharmacokinetic Properties of Δ^9 -Tetrahydrocannabinol in Oral Fluid. <i>Journal of Analytical Toxicology</i> , 2013, 37, 152-158.	2.8	17
94	High reward expectancy during methylphenidate depresses the dopaminergic response to gain and loss. <i>Social Cognitive and Affective Neuroscience</i> , 2017, 12, 311-318.	3.0	17
95	MDMA-induced indifference to negative sounds is mediated by the 5-HT _{2A} receptor. <i>Psychopharmacology</i> , 2018, 235, 481-490.	3.1	17
96	Pharmacokinetic properties of the synthetic cannabinoid JWH-018 in oral fluid after inhalation. <i>Drug Testing and Analysis</i> , 2018, 10, 644-650.	2.6	16
97	LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking. <i>Journal of Psychopharmacology</i> , 2022, 36, 348-359.	4.0	16
98	Effects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortium. <i>Psychopharmacology</i> , 2012, 222, 413-418.	3.1	15
99	Emotion recognition during cocaine intoxication. <i>European Neuropsychopharmacology</i> , 2015, 25, 1914-1921.	0.7	15
100	Opposite effects of cannabis and cocaine on performance monitoring. <i>European Neuropsychopharmacology</i> , 2016, 26, 1127-1139.	0.7	15
101	Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans. <i>Frontiers in Pharmacology</i> , 2018, 9, 713.	3.5	14
102	Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study. <i>Journal of Psychopharmacology</i> , 2020, 34, 856-863.	4.0	14
103	Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. <i>Scientific Reports</i> , 2018, 8, 1061.	3.3	13
104	Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. <i>Psychopharmacology</i> , 2022, 239, 1251-1261.	3.1	12
105	Validating lane drifts as a predictive measure of drug or sleepiness induced driving impairment. <i>Psychopharmacology</i> , 2020, 237, 877-886.	3.1	11
106	Acute Effects of 2C-E in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 233.	3.5	11
107	Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 202, 173118.	2.9	11
108	Comparing the effects of oxazepam and diazepam in actual highway driving and neurocognitive test performance: a validation study. <i>Psychopharmacology</i> , 2018, 235, 1283-1294.	3.1	10

#	ARTICLE	IF	CITATIONS
109	Driving under the influence of cocaine: Quantitative determination of basic drugs in oral fluid obtained during roadside controls and a controlled study with cocaine users. <i>Drug Testing and Analysis</i> , 2018, 10, 1285-1296.	2.6	10
110	The effects of the soluble guanylate cyclase stimulator riociguat on memory performance in healthy volunteers with a biperiden-induced memory impairment. <i>Psychopharmacology</i> , 2018, 235, 2407-2416.	3.1	10
111	False memory formation in cannabis users: a field study. <i>Psychopharmacology</i> , 2019, 236, 3439-3450.	3.1	10
112	Cocaine enhances figural, but impairs verbal "flexible" divergent thinking. <i>European Neuropsychopharmacology</i> , 2019, 29, 813-824.	0.7	10
113	Infusing pleasure: Mood effects of the consumption of a single cup of tea. <i>Appetite</i> , 2016, 103, 302-308.	3.7	9
114	The Setting Questionnaire for the Ayahuasca Experience: Questionnaire Development and Internal Structure. <i>Frontiers in Psychology</i> , 2021, 12, 679016.	2.1	9
115	Functional brain connectomes reflect acute and chronic cannabis use. <i>Scientific Reports</i> , 2022, 12, 2449.	3.3	9
116	Electroencephalography during on-the-road driving in older untreated insomnia patients and normal sleepers. <i>Biological Psychology</i> , 2015, 109, 20-28.	2.2	8
117	On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol. <i>Psychopharmacology</i> , 2016, 233, 3461-3469.	3.1	8
118	Excretion of metabolites of the synthetic cannabinoid JWH-018 in urine after controlled inhalation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 150, 162-168.	2.8	8
119	Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine. <i>Psychopharmacology</i> , 2018, 235, 2349-2356.	3.1	8
120	Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. <i>Drug Testing and Analysis</i> , 2019, 11, 1028-1034.	2.6	8
121	Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea. <i>Human Psychopharmacology</i> , 2022, 37, .	1.5	8
122	Up in Smoke: Comparability of THC Dosing across Performance Studies. <i>Neuropsychopharmacology</i> , 2006, 31, 2800-2801.	5.4	7
123	Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration: Can (R)/(S)-Concentration Ratios Help in Interpreting Forensic Cases?. <i>Journal of Analytical Toxicology</i> , 2021, 45, 985-992.	2.8	7
124	The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides. <i>Psychopharmacology</i> , 2022, 239, 1783-1796.	3.1	7
125	Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. <i>Psychopharmacology</i> , 2018, 235, 709-717.	3.1	6
126	Excretion of 4-fluoroamphetamine and three metabolites in urine after controlled oral ingestion. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 179, 113008.	2.8	6

#	ARTICLE	IF	CITATIONS
127	Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112845.	5.6	6
128	Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4-Fluoroamphetamine intoxication. <i>Human Psychopharmacology</i> , 2018, 33, e2680.	1.5	5
129	A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 225-235.	1.7	5
130	Semiquantitative Activity-Based Detection of JWH-018, a Synthetic Cannabinoid Receptor Agonist, in Oral Fluid after Vaping. <i>Analytical Chemistry</i> , 2020, 92, 6065-6071.	6.5	5
131	An explorative approach to understanding individual differences in driving performance and neurocognition in long-term benzodiazepine users. <i>Human Psychopharmacology</i> , 2021, 36, e2778.	1.5	5
132	A single dose of cocaine enhances prospective memory performance. <i>Journal of Psychopharmacology</i> , 2018, 32, 883-892.	4.0	4
133	Analysis of 4-Fluoroamphetamine in cerumen after controlled oral application. <i>Drug Testing and Analysis</i> , 2020, 12, 968-974.	2.6	4
134	Driving performance and neurocognitive skills of long-term users of sedating antidepressants. <i>Human Psychopharmacology</i> , 2021, 36, 1-12.	1.5	4
135	Roadside surveys of drinking and driving in Cameroon. <i>Traffic Injury Prevention</i> , 2021, 22, 349-354.	1.4	4
136	Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey. <i>British Journal of Pain</i> , 2022, 16, 619-631.	1.5	4
137	Use characteristics and harm potential of ecstasy in The Netherlands. <i>Drugs: Education, Prevention and Policy</i> , 2021, 28, 107-117.	1.3	3
138	Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis. <i>Journal of Psychopharmacology</i> , 2021, 35, 537-546.	4.0	3
139	Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure. <i>European Neuropsychopharmacology</i> , 2022, 57, 59-68.	0.7	3
140	Pharmacokinetics of Single Doses of Methadone and Buprenorphine in Blood and Oral Fluid in Healthy Volunteers and Correlation With Effects on Psychomotor and Cognitive Functions. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 489-493.	1.4	2
141	On-the-road driving performance of patients with central disorders of hypersomnolence. <i>Traffic Injury Prevention</i> , 2021, 22, 120-126.	1.4	2
142	Driving Impairment Following Vaporization of Cannabis—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1226.	7.4	1
143	Prevalence of alcohol among drivers, riders and pedestrians injured in road traffic crashes in Cameroon: a cross-sectional study. <i>International Journal of Injury Control and Safety Promotion</i> , 2022, 29, 340-347.	2.0	1
144	Cannabis Crashes: Myths & Truths. <i>Drug and Alcohol Review</i> , 2020, 39, 287-288.	2.1	0

#	ARTICLE	IF	CITATIONS
145	Reply to: Managing the high: developing legislation and detection methods for cannabis impairment. Nature Reviews Neuroscience, 2021, 22, 585-585.	10.2	0
146	Cannabis Use and Neuroadaptation: A Call for δ^9 -Tetrahydrocannabinol Challenge Studies. Frontiers in Psychiatry, 2022, 13, 870750.	2.6	0